Compare, Analyse RANBAXY LAB (500359 | RANBAXY~EQ) with SUN PHARMA (524715 | SUNPHARMA~EQ)
 
  
Compare another company

  
  

RANBAXY LAB vs SUN PHARMA - Comparison Results

  
  

RANBAXY LAB 
  Change

Ranbaxy is India's top pharmaceutical company, manufacturing and marketing branded generic pharmaceuticals products and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on US and European markets has helped it build deep product pipelines... More


SUN PHARMA 
Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
Stock Price Chart: ranbaxy lab Vs. sun pharma
Loading...
 
 
DO YOU LIKE THESE REPORTS? TELL US!
 Current Valuations
    RANBAXY LAB SUN PHARMA RANBAXY LAB/  
SUN PHARMA  
P/E (TTM) x -83.3 32.1 - View Chart
P/BV x 11.1 10.4 107.1% View Chart
Dividend Yield % 0.0 0.2 -  
 
 Financials
 
  EQUITY SHARE DATA
    RANBAXY LAB SUN PHARMA RANBAXY LAB/ 5-Yr Chart
    Mar-14 Mar-14 SUN PHARMA Click to enlarge
High Rs525653 80.4%   
Low Rs254493 51.5%   
Sales per share (Unadj.) Rs313.477.6 403.7%  
Earnings per share (Unadj.) Rs-25.615.2 -169.0%  
Cash flow per share (Unadj.) Rs-14.417.1 -83.9%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs78.089.4 87.2%  
Shares outstanding (eoy) m423.322,071.16 20.4%   
Bonus/Rights/Conversions ESOPB1:1-  
Price / Sales ratio x1.27.4 16.8%   
Avg P/E ratio x-15.237.8 -40.2%  
P/CF ratio (eoy) x-27.133.4 -81.0%  
Price / Book Value ratio x5.06.4 77.9%  
Dividend payout %09.9 0.0%   
Avg Mkt Cap Rs m164,8831,186,775 13.9%   
No. of employees `00015.314.0 109.3%   
Total wages/salary Rs m25,77520,744 124.2%   
Avg. sales/employee Rs Th8,672.211,486.0 75.5%   
Avg. wages/employee Rs Th1,684.61,481.7 113.7%   
Avg. net profit/employee Rs Th-709.32,243.9 -31.6%   
 
  INCOME DATA
Net Sales Rs m132,685160,804 82.5%  
Other income Rs m1,8282,647 69.1%   
Total revenues Rs m134,513163,451 82.3%   
Gross profit Rs m9,73270,017 13.9%  
Depreciation Rs m4,7624,092 116.4%   
Interest Rs m5,573442 1,261.1%   
Profit before tax Rs m1,22668,130 1.8%   
Minority Interest Rs m20-7,375 -0.3%   
Prior Period Items Rs m-1400-   
Extraordinary Inc (Exp) Rs m-8,643-22,318 38.7%   
Tax Rs m3,3147,022 47.2%   
Profit after tax Rs m-10,85231,415 -34.5%  
Gross profit margin %7.343.5 16.8%  
Effective tax rate %270.410.3 2,623.8%   
Net profit margin %-8.219.5 -41.9%  
 
  BALANCE SHEET DATA
Current assets Rs m70,357186,865 37.7%   
Current liabilities Rs m75,76059,896 126.5%   
Net working cap to sales %-4.179.0 -5.2%  
Current ratio x0.93.1 29.8%  
Inventory Days Days7671 107.1%  
Debtors Days Days5750 114.0%  
Net fixed assets Rs m53,83958,242 92.4%   
Share capital Rs m2,1172,071 102.2%   
"Free" reserves Rs m22,130163,019 13.6%   
Net worth Rs m33,031185,250 17.8%   
Long term debt Rs m24,744487 5,084.0%   
Total assets Rs m139,901293,708 47.6%  
Interest coverage x1.2155.2 0.8%   
Debt to equity ratio x0.70 28,513.1%  
Sales to assets ratio x0.90.5 173.2%   
Return on assets %-3.810.8 -34.8%  
Return on equity %-32.917.0 -193.7%  
Return on capital %-3.420.9 -16.3%  
Exports to sales %27.614.1 195.4%   
Imports to sales %6.93.6 191.8%   
Exports (fob) Rs m36,62222,713 161.2%   
Imports (cif) Rs m9,1485,779 158.3%   
Fx inflow Rs m50,93923,168 219.9%   
Fx outflow Rs m23,50512,629 186.1%   
Net fx Rs m27,43410,539 260.3%   
 
  CASH FLOW
From Operations Rs m-35,62439,592 -90.0%  
From Investments Rs m18,320-23,668 -77.4%  
From Financial Activity Rs m10,1625,066 200.6%  
Net Cashflow Rs m-7,14320,990 -34.0%  
 
 Share Holding
Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 63.4 0.0 -  
Indian inst/Mut Fund % 8.3 5.1 161.8%  
FIIs % 11.8 23.0 51.3%  
ADR/GDR % 1.5 0.0 -  
Free float % 15.0 8.3 180.7%  
Shareholders   182,721 133,026 137.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
Compare RANBAXY LAB With: AUROBINDO PHARMA | DR. REDDYS LAB | NOVARTIS | ASTRAZENECA PHARMA | MERCK LTD
Compare RANBAXY LAB With: ACTAVIS (US) | ADCOCK INGRAM (S. Africa) | MYLAN (US) | TEVA PHARMA (Israel)

Related Views on News

A drug where Ranbaxy scores over Dr Reddy's (Sector Info)

Jul 5, 2013

Equitymaster explains, which company is better of in the Isotretinoin drug in US.

Cipla Limited: On a growth drive (Cool Hand Luke)

Mar 21, 2014

Luke Verghese discusses that Cipla's financials are on a roll

GSK pharma's Open offer: Our view (Company Info)

Dec 17, 2013

Should investors take advantage of the buy back offer and offload shares of GSK Pharma?

Foreign investment in pharma; walking a thin line (What We're Reading)

Oct 9, 2013

Here is today's recommended reading list from Equitymaster...

Divi's Laboratories: Cash rich operations (Cool Hand Luke)

Sep 24, 2013

Luke Verghese discusses that Divi's Laboratories is professionally managed

More Views on News

Most Popular

Trading with an Investor's Attitude: Part I(Daily Profit Hunter)

Apr 14, 2015

Asad Dossani discusses how to trade with an investor's attitude. To be a successful trader, it is important to focus on long term performance.

TCS: Employee bonus hurts profits

Apr 16, 2015

TCS has reported a 1.1% QoQ fall in the topline and an decrease of 30.3% QoQ in the bottomline for the quarter ended March 2015.

How to miss the multi-bagger bus and still do well(The 5 Minute Wrapup)

Apr 18, 2015

Why it is ok to miss multi baggers provided you follow this simple investment rule.

Why Modi's dream of acche din will continue to remain a dream(The Daily Reckoning)

Apr 14, 2015

India needs to create jobs if it wants to create sustainable economic growth. And for that to happen the ease of doing business needs to improve dramatically.

Infosys: A weak quarter

Apr 24, 2015

Infosys has reported a 2.8% QoQ decrease in the topline and a fall of 4.7% QoQ in the bottomline for the quarter ended March 2015.

More

RANBAXY LAB STOCK QUOTE

BSE: 859.90 (5.63%)
NSE: 859.80 (5.63%)
Apr 1, 2015 (Close)
View Detailed Quote

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

RANBAXY LAB 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE RANBAXY LAB WITH

MARKET STATS

  1. Go